|Denosumab for prevention of fractures in postmenopausal women with osteoporosis|
SR Cummings, JS Martin, MR McClung, ES Siris, R Eastell, IR Reid, ...
New England Journal of Medicine 361 (8), 756-765, 2009
|Romosozumab in postmenopausal women with low bone mineral density|
MR McClung, A Grauer, S Boonen, MA Bolognese, JP Brown, ...
New England Journal of Medicine 370 (5), 412-420, 2014
|Romosozumab treatment in postmenopausal women with osteoporosis|
F Cosman, DB Crittenden, JD Adachi, N Binkley, E Czerwinski, S Ferrari, ...
New England Journal of Medicine 375 (16), 1532-1543, 2016
|Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 …|
JP Brown, RL Prince, C Deal, RR Recker, DP Kiel, LH De Gregorio, ...
Journal of bone and mineral research 24 (1), 153-161, 2009
|Vertebral bone density in children: effect of puberty.|
V Gilsanz, DT Gibbens, TF Roe, M Carlson, MO Senac, MI Boechat, ...
Radiology 166 (3), 847-850, 1988
|Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men|
A Menkes, S Mazel, RA Redmond, K Koffler, CR Libanati, CM Gundberg, ...
Journal of applied physiology 74 (5), 2478-2484, 1993
|Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension|
S Papapoulos, R Chapurlat, C Libanati, ML Brandi, JP Brown, ...
Journal of Bone and Mineral Research 27 (3), 694-701, 2012
|Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate|
E Seeman, PD Delmas, DA Hanley, D Sellmeyer, AM Cheung, E Shane, ...
Journal of Bone and Mineral Research 25 (8), 1886-1894, 2010
|The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study|
S Papapoulos, K Lippuner, C Roux, CJF Lin, DL Kendler, EM Lewiecki, ...
Osteoporosis international 26 (12), 2773-2783, 2015
|Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open …|
BL Langdahl, C Libanati, DB Crittenden, MA Bolognese, JP Brown, ...
The Lancet 390 (10102), 1585-1594, 2017
|Effects of denosumab on bone turnover markers in postmenopausal osteoporosis|
R Eastell, C Christiansen, A Grauer, S Kutilek, C Libanati, MR McClung, ...
Journal of Bone and Mineral Research 26 (3), 530-537, 2011
|Effects of strength training on bone mineral density: hormonal and bone turnover relationships|
AS Ryan, MS Treuth, MA Rubin, JP Miller, BJ Nicklas, DM Landis, ...
Journal of applied physiology 77 (4), 1678-1684, 1994
|Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences|
B Ettinger, S Sidney, SR Cummings, C Libanati, DD Bikle, IS Tekawa, ...
The Journal of Clinical Endocrinology & Metabolism 82 (2), 429-434, 1997
|National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges|
D Bauer, J Krege, N Lane, E Leary, C Libanati, P Miller, G Myers, ...
Osteoporosis International 23 (10), 2425-2433, 2012
|Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures|
M Austin, YC Yang, E Vittinghoff, S Adami, S Boonen, DC Bauer, ...
Journal of Bone and Mineral Research 27 (3), 687-693, 2012
|Differing effects of denosumab and alendronate on cortical and trabecular bone|
RM Zebaze, C Libanati, M Austin, A Ghasem-Zadeh, DA Hanley, ...
Bone 59, 173-179, 2014
|Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX|
EV McCloskey, H Johansson, A Oden, M Austin, E Siris, A Wang, ...
Journal of Bone and Mineral Research 27 (7), 1480-1486, 2012
|Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids|
S Mohan, C Libanati, C Dony, K Lang, N Srinivasan, DJ Baylink
The Journal of Clinical Endocrinology & Metabolism 80 (9), 2638-2645, 1995
|Biochemical markers of bone turnover for the clinical assessment of bone metabolism|
AK Taylor, SA Lueken, C Libanati, DJ Baylink
Rheumatic Disease Clinics of North America 20 (3), 589-607, 1994
|Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray …|
K Engelke, C Libanati, Y Liu, H Wang, M Austin, T Fuerst, B Stampa, ...
Bone 45 (1), 110-118, 2009